课题基金 / 基金详情

Tufts Clinical and Translational Science Institute

Tufts Clinical and Translational Science Institute
塔夫茨临床与转化科学研究所
批准号:
10622002
负责人:
Harry P. Selker
金额:
$1139.42万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-05-01 至 2030-04-30

项目摘要

项目成果

Harry P. Selker的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
TUFTS CTSI OVERALL PROJECT SUMMARY Over its 14 years, Tufts Clinical and Translational Science Institute (CTSI) has brought together partners and collaborators and has grown programs and activities to catalyze clinical and translational research (CTR) and to advance innovation in clinical and translational science (CTS). We focus on what we are best suited to do, based on our skills, resources, partners, and opportunities. Thereby, we provide outstanding services, resources, education, and mentorship, and conduct innovative research contributing to the field of CTS, locally and nationally. With this application, retaining our important structural features of integration across all of Tufts University, of having purposefully-selected partners, and adhering to our foundational principles, we are pleased to further grow our offerings and ambitions leveraging our long-standing partners’ contributions and assets and by adding the special assets of new partners. With growth, our foundational principles have not changed. We actively support the full spectrum of translational research, we practice “broadly-engaged team science,” and we are active collaborators, embracing our role as “the extrovert CTSA.” We believe that only by having systems and processes to continually assess and improve methods and operational principles will we achieve CTR/CTS excellence. We practice inclusive communications and work to advance health equity. And we insist that wherever work is on the T.5-T4 continuum, CTR must have a clear line of sight to potential ultimate impact on health. In addition to these foundational principles, in all we do, we reflexively look for opportunities to contribute novel research methods. Development, demonstration, and dissemination of new methods and approaches are hallmarks of our work, regardless of domain. Also, we manifest our belief that rigorous role-specific inclusive education and training are fundamental to excellence and advancing CTR/CTS. In service of these principles, our aims are: Overall AIM 1: Harness the collective impact of Tufts CTSI to advance CTS and improve public health through responsive Hub leadership, an inclusive and collaborative culture, and continuous improvement of programs and research. Overall AIM 2: Provide outstanding education, training, and mentoring, tailored to different roles and disciplines, to develop an expert and diverse CTS workforce, and share these resources nationally. Overall AIM 3: Cultivate broadly-engaged team science, with active inclusion of all stakeholders, to promote relevant and impactful translation for diverse populations and to promote health equity. Overall AIM 4: Create the environment, resources, and services to stimulate and support the full spectrum of CTS by leveraging the diverse expertise and assets of Tufts CTSI partners. Overall AIM 5: Foster translation by developing, demonstrating, and disseminating innovations that address significant translational roadblocks and provide generalizable translational insights and solutions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tufts Clinical and Translational Science Institute (Clinical Trial Design Labs Supplement)
  • 批准号:
    10844980
  • 项目类别:
  • 资助金额:
    $97.51万
  • 财政年份:
    2023
  • 负责人:
    Harry P. Selker
  • 依托单位:
Tufts Clinical and Translational Science Institute
  • 批准号:
    9816143
  • 项目类别:
  • 资助金额:
    $13.45万
  • 财政年份:
    2018
  • 负责人:
    Harry P. Selker
  • 依托单位:
Tufts Clinical and Translational Science Institute
  • 批准号:
    10159334
  • 项目类别:
  • 资助金额:
    $943.36万
  • 财政年份:
    2018
  • 负责人:
    Harry P. Selker
  • 依托单位:
Tufts Clinical and Translational Science Institute
  • 批准号:
    10412102
  • 项目类别:
  • 资助金额:
    $966.99万
  • 财政年份:
    2018
  • 负责人:
    Harry P. Selker
  • 依托单位:
海外基金